Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial. Belin, L., Kamal, M., Mauborgne, C., Plancher, C., Mulot, F., Delord, J., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Ricci, F., Alt, M., Loirat, D., Sablin, M., Paoletti, X., Servois, V., & Le Tourneau, C. Annals of Oncology, 28(3):590–596, March, 2017.
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial [link]Paper  doi  abstract   bibtex   
Background: Several studies used the ratio of progression-free survival (PFS) on genotype-matched treatment to PFS on genotype-unmatched treatment to assess the efficacy of therapy guided by patients’ tumor molecular profiling. We evaluated the PFS ratio from patients who cross-over in the SHIVA trial. Patients and methods: The primary end point of the SHIVA trial was to compare PFS on molecularly targeted agents (MTAs) based on tumor molecular profiling and treatment at physician’s choice (TPC) in patients with any kind of cancer who had failed standard-of-care therapy. The experimental treatment included only marketed MTAs given outside their indications according to a pre-specified treatment algorithm. Patients were allowed to cross-over at disease progression in both arms. Response was evaluated according to RECIST 1.1 at randomization and at cross-over. We evaluated the ratio of PFS on MTA (PFSMTA) to PFS on TPC (PFSTPC) in patients who crossed-over. Results: Among 741 patients enrolled in the SHIVA trial, 197 were randomized, and 95 crossed-over, including 70 patients from the TPC to the MTA arm and 25 patients from the MTA to the TPC arm. Two patients crossed-over in the TPC arm without disease progression. The PFSMTA/PFSTPC ratio exceeded 1.3 in 37% of patients who crossed-over from the TPC to the MTA arm. The PFSMTA/PFSTPC ratio exceeded 1.3 in 61% of patients who crossed-over from the MTA arm to the TPC arm. Conclusions: The cross-over analysis of the SHIVA trial identified 37% of patients who crossed-over from TPC to MTA with a PFSMTA/PFSTPC ratio exceeding 1.3.
@article{belin_randomized_2017-1,
	title = {Randomized phase {II} trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the {SHIVA} trial},
	volume = {28},
	issn = {09237534},
	shorttitle = {Randomized phase {II} trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer},
	url = {https://linkinghub.elsevier.com/retrieve/pii/S0923753419319787},
	doi = {10.1093/annonc/mdw666},
	abstract = {Background: Several studies used the ratio of progression-free survival (PFS) on genotype-matched treatment to PFS on genotype-unmatched treatment to assess the efficacy of therapy guided by patients’ tumor molecular profiling. We evaluated the PFS ratio from patients who cross-over in the SHIVA trial. Patients and methods: The primary end point of the SHIVA trial was to compare PFS on molecularly targeted agents (MTAs) based on tumor molecular profiling and treatment at physician’s choice (TPC) in patients with any kind of cancer who had failed standard-of-care therapy. The experimental treatment included only marketed MTAs given outside their indications according to a pre-specified treatment algorithm. Patients were allowed to cross-over at disease progression in both arms. Response was evaluated according to RECIST 1.1 at randomization and at cross-over. We evaluated the ratio of PFS on MTA (PFSMTA) to PFS on TPC (PFSTPC) in patients who crossed-over. Results: Among 741 patients enrolled in the SHIVA trial, 197 were randomized, and 95 crossed-over, including 70 patients from the TPC to the MTA arm and 25 patients from the MTA to the TPC arm. Two patients crossed-over in the TPC arm without disease progression. The PFSMTA/PFSTPC ratio exceeded 1.3 in 37\% of patients who crossed-over from the TPC to the MTA arm. The PFSMTA/PFSTPC ratio exceeded 1.3 in 61\% of patients who crossed-over from the MTA arm to the TPC arm. Conclusions: The cross-over analysis of the SHIVA trial identified 37\% of patients who crossed-over from TPC to MTA with a PFSMTA/PFSTPC ratio exceeding 1.3.},
	language = {en},
	number = {3},
	urldate = {2021-04-28},
	journal = {Annals of Oncology},
	author = {Belin, L. and Kamal, M. and Mauborgne, C. and Plancher, C. and Mulot, F. and Delord, J.-P. and Gonçalves, A. and Gavoille, C. and Dubot, C. and Isambert, N. and Campone, M. and Trédan, O. and Ricci, F. and Alt, M. and Loirat, D. and Sablin, M.-P. and Paoletti, X. and Servois, V. and Le Tourneau, C.},
	month = mar,
	year = {2017},
	pages = {590--596},
	file = {!Learning about aggregate DCEA-Aug2020 (1).pdf:/Users/neil.hawkins/Zotero/storage/9KW2AMCC/!Learning about aggregate DCEA-Aug2020 (1).pdf:application/pdf;!Learning about aggregate DCEA-Aug2020.pdf:/Users/neil.hawkins/Zotero/storage/5FG32Q2C/!Learning about aggregate DCEA-Aug2020.pdf:application/pdf;1-s2.0-S0002914921002071-main.pdf:/Users/neil.hawkins/Zotero/storage/6CT98BBZ/1-s2.0-S0002914921002071-main.pdf:application/pdf;1-s2.0-S089543561731137X-main (1).pdf:/Users/neil.hawkins/Zotero/storage/5CJ5W6T2/1-s2.0-S089543561731137X-main (1).pdf:application/pdf;1-s2.0-S089543561731137X-main.pdf:/Users/neil.hawkins/Zotero/storage/I4EBEZLJ/1-s2.0-S089543561731137X-main.pdf:application/pdf;1-s2.0-S1051044318308029-main (1).pdf:/Users/neil.hawkins/Zotero/storage/A54RKJ7D/1-s2.0-S1051044318308029-main (1).pdf:application/pdf;1-s2.0-S1098301519301524-main.pdf:/Users/neil.hawkins/Zotero/storage/TTB9I9CX/1-s2.0-S1098301519301524-main.pdf:application/pdf;1-s2.0-S1098301519301524-mmc1.docx:/Users/neil.hawkins/Zotero/storage/PQW8G2XA/1-s2.0-S1098301519301524-mmc1.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document;1-s2.0-S1098301519322454-main.pdf:/Users/neil.hawkins/Zotero/storage/KXAMJ3JV/1-s2.0-S1098301519322454-main.pdf:application/pdf;1-s2.0-S1201971219303972-main.pdf:/Users/neil.hawkins/Zotero/storage/YZR5W6XT/1-s2.0-S1201971219303972-main.pdf:application/pdf;06_Presentation Claire Watkins final 2015-06-16.pdf:/Users/neil.hawkins/Zotero/storage/3TFGTEED/06_Presentation Claire Watkins final 2015-06-16.pdf:application/pdf;10.1177_0969141315600192.pdf:/Users/neil.hawkins/Zotero/storage/ZGKZHGA5/10.1177_0969141315600192.pdf:application/pdf;17-04w.pdf:/Users/neil.hawkins/Zotero/storage/L88YNJ39/17-04w.pdf:application/pdf;34.full.pdf:/Users/neil.hawkins/Zotero/storage/KZ8MV5GU/34.full.pdf:application/pdf;156.full.pdf:/Users/neil.hawkins/Zotero/storage/HH2SM8UK/156.full.pdf:application/pdf;198_2020_Article_5536.pdf:/Users/neil.hawkins/Zotero/storage/F4TUTRIC/198_2020_Article_5536.pdf:application/pdf;672.full.pdf:/Users/neil.hawkins/Zotero/storage/76CRNTRP/672.full.pdf:application/pdf;970.full.pdf:/Users/neil.hawkins/Zotero/storage/M3F3LG7G/970.full.pdf:application/pdf;1136.pdf:/Users/neil.hawkins/Zotero/storage/CFTWNDLQ/1136.pdf:application/pdf;1477-7525-6-51.pdf:/Users/neil.hawkins/Zotero/storage/6GAPQV55/1477-7525-6-51.pdf:application/pdf;1756-185X.13616.pdf:/Users/neil.hawkins/Zotero/storage/DCK3I8BA/1756-185X.13616.pdf:application/pdf;8649_hse_2018_dataset_documentation.pdf:/Users/neil.hawkins/Zotero/storage/TW7JRXL5/8649_hse_2018_dataset_documentation.pdf:application/pdf;11136_2015_Article_1108.pdf:/Users/neil.hawkins/Zotero/storage/DZ69K4LH/11136_2015_Article_1108.pdf:application/pdf;12325_2020_1303_MOESM1_ESM.docx:/Users/neil.hawkins/Zotero/storage/SPF3TJKB/12325_2020_1303_MOESM1_ESM.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document;12325_2020_Article_1303.pdf:/Users/neil.hawkins/Zotero/storage/VHZYPNJM/12325_2020_Article_1303.pdf:application/pdf;12913_2015_Article_1061 (1).pdf:/Users/neil.hawkins/Zotero/storage/ZFY3WYQ4/12913_2015_Article_1061 (1).pdf:application/pdf;12913_2015_Article_1061.pdf:/Users/neil.hawkins/Zotero/storage/YKGVLF2D/12913_2015_Article_1061.pdf:application/pdf;160518_Final paper_with cover.pdf:/Users/neil.hawkins/Zotero/storage/SYWUBFD6/160518_Final paper_with cover.pdf:application/pdf;0272989x16638312.pdf:/Users/neil.hawkins/Zotero/storage/ATJ5PRGT/0272989x16638312.pdf:application/pdf;0272989x17696997.pdf:/Users/neil.hawkins/Zotero/storage/DIIM5ZKR/0272989x17696997.pdf:application/pdf;0272989x18801312.pdf:/Users/neil.hawkins/Zotero/storage/WD3CKRTD/0272989x18801312.pdf:application/pdf;0272989x20983315.pdf:/Users/neil.hawkins/Zotero/storage/RUWWZBAE/0272989x20983315.pdf:application/pdf;0272989x211014114.pdf:/Users/neil.hawkins/Zotero/storage/C62NYUKF/0272989x211014114.pdf:application/pdf;0272989x211029556.pdf:/Users/neil.hawkins/Zotero/storage/HPXIJBDX/0272989x211029556.pdf:application/pdf;460132.pdf:/Users/neil.hawkins/Zotero/storage/G7WQVZ9X/460132.pdf:application/pdf;487502.pdf:/Users/neil.hawkins/Zotero/storage/GYQS6BT5/487502.pdf:application/pdf;705640.pdf:/Users/neil.hawkins/Zotero/storage/739B723K/705640.pdf:application/pdf;1536867x20909693.pdf:/Users/neil.hawkins/Zotero/storage/P58YM7SM/1536867x20909693.pdf:application/pdf;3001495.pdf:/Users/neil.hawkins/Zotero/storage/UB42AAF9/3001495.pdf:application/pdf;3002700.pdf:/Users/neil.hawkins/Zotero/storage/93NUV6PU/3002700.pdf:application/pdf;6604973.pdf:/Users/neil.hawkins/Zotero/storage/3J77R65X/6604973.pdf:application/pdf;09546634.2021.pdf:/Users/neil.hawkins/Zotero/storage/62X6WDE7/09546634.2021.pdf:application/pdf;32701446.pdf:/Users/neil.hawkins/Zotero/storage/JL53BSRV/32701446.pdf:application/pdf;82527019.pdf:/Users/neil.hawkins/Zotero/storage/QGD2SN97/82527019.pdf:application/pdf;237397345.pdf:/Users/neil.hawkins/Zotero/storage/9NN5CVWT/237397345.pdf:application/pdf;A Value Attribution Framework for Combination Therapies Takeda Whitepaper.pdf:/Users/neil.hawkins/Zotero/storage/3QTQINPF/A Value Attribution Framework for Combination Therapies Takeda Whitepaper.pdf:application/pdf;A_clinical_trial_is_a_success.pdf:/Users/neil.hawkins/Zotero/storage/539TYKDF/A_clinical_trial_is_a_success.pdf:application/pdf;A-general-linear-modelling-framework-for-pair-wise-and-network-meta-analysis-of-randomised-controlled-trials..pdf:/Users/neil.hawkins/Zotero/storage/MMFV9E5Q/A-general-linear-modelling-framework-for-pair-wise-and-network-meta-analysis-of-randomised-controlled-trials..pdf:application/pdf;A10.pdf:/Users/neil.hawkins/Zotero/storage/HYGLLGL8/A10.pdf:application/pdf;Abrishami-2011.pdf:/Users/neil.hawkins/Zotero/storage/HB2QIT3W/Abrishami-2011.pdf:application/pdf;Advance-HTA-Final-deliverable.pdf:/Users/neil.hawkins/Zotero/storage/N6SYVHZW/Advance-HTA-Final-deliverable.pdf:application/pdf;Akpinar2019_Article_TheCostsOfIndustry-SponsoredMe.pdf:/Users/neil.hawkins/Zotero/storage/2BACDUK4/Akpinar2019_Article_TheCostsOfIndustry-SponsoredMe.pdf:application/pdf;anovaunbalanced.pdf:/Users/neil.hawkins/Zotero/storage/3T5DHUTU/anovaunbalanced.pdf:application/pdf;Aroda et al. - 2019 - Incorporating and interpreting regulatory guidance.pdf:/Users/neil.hawkins/Zotero/storage/49NKZPAF/Aroda et al. - 2019 - Incorporating and interpreting regulatory guidance.pdf:application/pdf;B0255-nhs-commercial-framework-for-new-medicines.pdf:/Users/neil.hawkins/Zotero/storage/TCQM9TMB/B0255-nhs-commercial-framework-for-new-medicines.pdf:application/pdf;Belin et al. - 2017 - Randomized phase II trial comparing molecularly ta.pdf:/Users/neil.hawkins/Zotero/storage/FWUCKI5C/Belin et al. - 2017 - Randomized phase II trial comparing molecularly ta.pdf:application/pdf;Belin et al. - 2017 - Randomized phase II trial comparing molecularly ta.pdf:/Users/neil.hawkins/Zotero/storage/HTVH4RCY/Belin et al. - 2017 - Randomized phase II trial comparing molecularly ta.pdf:application/pdf;bimj.201900339.pdf:/Users/neil.hawkins/Zotero/storage/4KJ3VV62/bimj.201900339.pdf:application/pdf;Biologics_2009.pdf:/Users/neil.hawkins/Zotero/storage/EQZL93RK/Biologics_2009.pdf:application/pdf;bjc2016414.pdf:/Users/neil.hawkins/Zotero/storage/UYN3BSBT/bjc2016414.pdf:application/pdf;bjd.19039.pdf:/Users/neil.hawkins/Zotero/storage/VJ9TIYC6/bjd.19039.pdf:application/pdf;bjd19039-sup-0001-files1.pdf:/Users/neil.hawkins/Zotero/storage/3HK8JY3W/bjd19039-sup-0001-files1.pdf:application/pdf;bmj.c2442.full.pdf:/Users/neil.hawkins/Zotero/storage/8B3XNS7B/bmj.c2442.full.pdf:application/pdf;bmj.i6538.full.pdf:/Users/neil.hawkins/Zotero/storage/36M8G7UD/bmj.i6538.full.pdf:application/pdf;bmj.j2099.full (1).pdf:/Users/neil.hawkins/Zotero/storage/96657C8I/bmj.j2099.full (1).pdf:application/pdf;bmj.j2099.full.pdf:/Users/neil.hawkins/Zotero/storage/7PWD3BMG/bmj.j2099.full.pdf:application/pdf;bmj.l2068.full.pdf:/Users/neil.hawkins/Zotero/storage/UKZ8LIXV/bmj.l2068.full.pdf:application/pdf;bmjcred00436-0013.pdf:/Users/neil.hawkins/Zotero/storage/S7C58E4E/bmjcred00436-0013.pdf:application/pdf;Booth Methodological-Update-on-use-of-qualitative-evidence-in-HTA-Final-20-4-20-Final.pdf:/Users/neil.hawkins/Zotero/storage/4E7HSBKR/Booth Methodological-Update-on-use-of-qualitative-evidence-in-HTA-Final-20-4-20-Final.pdf:application/pdf;CDTP2021-8561350.pdf:/Users/neil.hawkins/Zotero/storage/IRUB7ULM/CDTP2021-8561350.pdf:application/pdf;CE and equity impact final.pdf:/Users/neil.hawkins/Zotero/storage/NBW4FQR9/CE and equity impact final.pdf:application/pdf;Cefiderocol assessment report 05 11 2021.pdf:/Users/neil.hawkins/Zotero/storage/ZEU6NLLB/Cefiderocol assessment report 05 11 2021.pdf:application/pdf;cer-2018-0065.pdf:/Users/neil.hawkins/Zotero/storage/MLJI47EG/cer-2018-0065.pdf:application/pdf;CHERP69_Informing_approval_pricing_and_research_decisions_for_health_technologies (1).pdf:/Users/neil.hawkins/Zotero/storage/AAACBI8J/CHERP69_Informing_approval_pricing_and_research_decisions_for_health_technologies (1).pdf:application/pdf;CHERP69_Informing_approval_pricing_and_research_decisions_for_health_technologies.pdf:/Users/neil.hawkins/Zotero/storage/8TLNFP9H/CHERP69_Informing_approval_pricing_and_research_decisions_for_health_technologies.pdf:application/pdf;CHERP175_HTA_guidance_NICE.pdf:/Users/neil.hawkins/Zotero/storage/SMEE4Q55/CHERP175_HTA_guidance_NICE.pdf:application/pdf;clpt2010279a (1).pdf:/Users/neil.hawkins/Zotero/storage/CW9LU9RG/clpt2010279a (1).pdf:application/pdf;clpt2010279a.pdf:/Users/neil.hawkins/Zotero/storage/3WJ43HXC/clpt2010279a.pdf:application/pdf;committee-papers.pdf:/Users/neil.hawkins/Zotero/storage/E4WC8QKQ/committee-papers.pdf:application/pdf;Copy of Japan_EQ-5D.xlsm:/Users/neil.hawkins/Zotero/storage/KNAVMWPJ/Copy of Japan_EQ-5D.xlsm:application/vnd.ms-excel.sheet.macroEnabled.12;Core-Guide_Correlation-Structures-in-Longitudinal-Data-Analysis_09-19-17.pdf:/Users/neil.hawkins/Zotero/storage/EU79MJFS/Core-Guide_Correlation-Structures-in-Longitudinal-Data-Analysis_09-19-17.pdf:application/pdf;Cost-effectiveness_of_the_faecal_immunochemical_te.pdf:/Users/neil.hawkins/Zotero/storage/FP845XZD/Cost-effectiveness_of_the_faecal_immunochemical_te.pdf:application/pdf;CPRD Synthetic CVD Data Specification.pdf:/Users/neil.hawkins/Zotero/storage/T3PDDX4F/CPRD Synthetic CVD Data Specification.pdf:application/pdf;cvm-1-1-025.pdf:/Users/neil.hawkins/Zotero/storage/5VA2K5H8/cvm-1-1-025.pdf:application/pdf;d41586-020-02884-3.pdf:/Users/neil.hawkins/Zotero/storage/T93G89S3/d41586-020-02884-3.pdf:application/pdf;developing-nice-guidelines-the-manual-pdf-72286708700869.pdf:/Users/neil.hawkins/Zotero/storage/NLDS858I/developing-nice-guidelines-the-manual-pdf-72286708700869.pdf:application/pdf;dgz203 (1).pdf:/Users/neil.hawkins/Zotero/storage/9EYRTGSB/dgz203 (1).pdf:application/pdf;dgz203.pdf:/Users/neil.hawkins/Zotero/storage/ZMYXSLLW/dgz203.pdf:application/pdf;diagnostics-assessment-programme-manual.pdf:/Users/neil.hawkins/Zotero/storage/GSMMQA4C/diagnostics-assessment-programme-manual.pdf:application/pdf;dismantling-cognitive-behaviour-therapy-for-panic-disorder-a-systematic-review-and-component-network-meta-analysis.pdf:/Users/neil.hawkins/Zotero/storage/BUBH5PNW/dismantling-cognitive-behaviour-therapy-for-panic-disorder-a-systematic-review-and-component-network-meta-analysis.pdf:application/pdf;djv153.pdf:/Users/neil.hawkins/Zotero/storage/HHEBP9SL/djv153.pdf:application/pdf;Document (1).PDF:/Users/neil.hawkins/Zotero/storage/MEPSYWZ7/Document (1).PDF:application/pdf;Document (2).PDF:/Users/neil.hawkins/Zotero/storage/ZVSGY8V3/Document (2).PDF:application/pdf;Document (3).PDF:/Users/neil.hawkins/Zotero/storage/4ZSZNR3Z/Document (3).PDF:application/pdf;Document (4).PDF:/Users/neil.hawkins/Zotero/storage/3AX9UJSG/Document (4).PDF:application/pdf;Document.PDF:/Users/neil.hawkins/Zotero/storage/U84H2DHH/Document.PDF:application/pdf;dyz137.pdf:/Users/neil.hawkins/Zotero/storage/RAHRFSIZ/dyz137.pdf:application/pdf;e000091.full.pdf:/Users/neil.hawkins/Zotero/storage/5G9L8QES/e000091.full.pdf:application/pdf;e002152.full.pdf:/Users/neil.hawkins/Zotero/storage/GM8VE6T5/e002152.full.pdf:application/pdf;e014953.full.pdf:/Users/neil.hawkins/Zotero/storage/RCV32FNS/e014953.full.pdf:application/pdf;e017186.full.pdf:/Users/neil.hawkins/Zotero/storage/WV9TCM7D/e017186.full.pdf:application/pdf;e046417.full.pdf:/Users/neil.hawkins/Zotero/storage/QKC8BI3T/e046417.full.pdf:application/pdf;eb-2015-102275.full.pdf:/Users/neil.hawkins/Zotero/storage/NNSRDHB5/eb-2015-102275.full.pdf:application/pdf;ehaa034.pdf:/Users/neil.hawkins/Zotero/storage/8NVJRDUD/ehaa034.pdf:application/pdf;elicit1.pdf:/Users/neil.hawkins/Zotero/storage/CW4C2FL2/elicit1.pdf:application/pdf;Elicitation-NICE-final-report-York_01042020.pdf:/Users/neil.hawkins/Zotero/storage/APSVG4IL/Elicitation-NICE-final-report-York_01042020.pdf:application/pdf;Estimating an EQ-5D population value set.pdf:/Users/neil.hawkins/Zotero/storage/VZP4WPFW/Estimating an EQ-5D population value set.pdf:application/pdf;Evaluating-Preventative-Investments.pdf:/Users/neil.hawkins/Zotero/storage/3UZ3Q32B/Evaluating-Preventative-Investments.pdf:application/pdf;Evaluation_Playbook_Jul21.pdf:/Users/neil.hawkins/Zotero/storage/7H8AQP66/Evaluation_Playbook_Jul21.pdf:application/pdf;Evidence_summary-_Bowel_Cancer_2018.pdf:/Users/neil.hawkins/Zotero/storage/5NHH2GUE/Evidence_summary-_Bowel_Cancer_2018.pdf:application/pdf;Facon 2018 (ASH).pdf:/Users/neil.hawkins/Zotero/storage/W89WRZYS/Facon 2018 (ASH).pdf:application/pdf;Facon 2019.pdf:/Users/neil.hawkins/Zotero/storage/6DTPMU6S/Facon 2019.pdf:application/pdf;Fenwick4172 (1).pdf:/Users/neil.hawkins/Zotero/storage/7GQ3H6A3/Fenwick4172 (1).pdf:application/pdf;Fenwick4172 (2).pdf:/Users/neil.hawkins/Zotero/storage/S6HA3L7V/Fenwick4172 (2).pdf:application/pdf;Fenwick4172.pdf:/Users/neil.hawkins/Zotero/storage/3SVXQQVX/Fenwick4172.pdf:application/pdf;FinalBowelCancerSummaryReport-Apr07.pdf:/Users/neil.hawkins/Zotero/storage/XZ5RFFBM/FinalBowelCancerSummaryReport-Apr07.pdf:application/pdf;FirstSubmission1801431.pdf:/Users/neil.hawkins/Zotero/storage/XXGC9NRJ/FirstSubmission1801431.pdf:application/pdf;fmed-07-618163.pdf:/Users/neil.hawkins/Zotero/storage/IKGPKZDG/fmed-07-618163.pdf:application/pdf;fon-2021-0300.pdf:/Users/neil.hawkins/Zotero/storage/XXGR3MQC/fon-2021-0300.pdf:application/pdf;formsubmission-apply-grant-shotgun-certificate-fsg-13760-21-4343-c.pdf:/Users/neil.hawkins/Zotero/storage/5K5HLBE3/formsubmission-apply-grant-shotgun-certificate-fsg-13760-21-4343-c.pdf:application/pdf;foundation_licence_guide[1]-2.pdf:/Users/neil.hawkins/Zotero/storage/66ZGE8MZ/foundation_licence_guide[1]-2.pdf:application/pdf;foundation-licence.pdf:/Users/neil.hawkins/Zotero/storage/QT8AR9RT/foundation-licence.pdf:application/pdf;full-guideline-pdf-190130941.pdf:/Users/neil.hawkins/Zotero/storage/4UHU8UZH/full-guideline-pdf-190130941.pdf:application/pdf;gfx380 (1).pdf:/Users/neil.hawkins/Zotero/storage/NRQYEV5E/gfx380 (1).pdf:application/pdf;gfx380 (2).pdf:/Users/neil.hawkins/Zotero/storage/LKUHN7HU/gfx380 (2).pdf:application/pdf;gfx380.pdf:/Users/neil.hawkins/Zotero/storage/NV8ULZ9I/gfx380.pdf:application/pdf;Giannini2021_Article_BurdenOfDiseaseAndClinicalTarg.pdf:/Users/neil.hawkins/Zotero/storage/PJQ7GX7R/Giannini2021_Article_BurdenOfDiseaseAndClinicalTarg.pdf:application/pdf;GOe_FP_AMR_Report_final.pdf:/Users/neil.hawkins/Zotero/storage/GDE47QMY/GOe_FP_AMR_Report_final.pdf:application/pdf;gp_overview_guide.pdf:/Users/neil.hawkins/Zotero/storage/L9I6UCK3/gp_overview_guide.pdf:application/pdf;Gries2017_Article_UtilityEstimatesOfDisease-Spec.pdf:/Users/neil.hawkins/Zotero/storage/BIYF5C4I/Gries2017_Article_UtilityEstimatesOfDisease-Spec.pdf:application/pdf;Guidance-on-choosing-qualitative-evidence-synthesis-methods-for-use-in-HTA-of-complex-interventions.pdf:/Users/neil.hawkins/Zotero/storage/5TJAUFZ3/Guidance-on-choosing-qualitative-evidence-synthesis-methods-for-use-in-HTA-of-complex-interventions.pdf:application/pdf;hamerle2.pdf:/Users/neil.hawkins/Zotero/storage/3VEKA36I/hamerle2.pdf:application/pdf;hanley_mcneil_radiology_82.pdf:/Users/neil.hawkins/Zotero/storage/LXUC2ML5/hanley_mcneil_radiology_82.pdf:application/pdf;Hawley S et al Comorbidities in XLH Rheumatology 2020.pdf:/Users/neil.hawkins/Zotero/storage/C4EREFK5/Hawley S et al Comorbidities in XLH Rheumatology 2020.pdf:application/pdf;Health technology assessment HTA and economic evaluation efficiency or fairness first.pdf:/Users/neil.hawkins/Zotero/storage/T6FKH4BK/Health technology assessment HTA and economic evaluation efficiency or fairness first.pdf:application/pdf;Health-related quality-of-life among survivors of acute kidney injury in the intensive care unit_a systematic review_Villeneuve_IntenCareMed_2016.pdf:/Users/neil.hawkins/Zotero/storage/FL8BSL32/Health-related quality-of-life among survivors of acute kidney injury in the intensive care unit_a systematic review_Villeneuve_IntenCareMed_2016.pdf:application/pdf;Heerspink - DAPA-CKD Primary Pub - NEJM 2020.pdf:/Users/neil.hawkins/Zotero/storage/39XLTN29/Heerspink - DAPA-CKD Primary Pub - NEJM 2020.pdf:application/pdf;hlthaff.2014.1003.pdf:/Users/neil.hawkins/Zotero/storage/ZVBCZ2WL/hlthaff.2014.1003.pdf:application/pdf;HST-interim-methods-process-guide-may-17.pdf:/Users/neil.hawkins/Zotero/storage/DITBJPTS/HST-interim-methods-process-guide-may-17.pdf:application/pdf;ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf:/Users/neil.hawkins/Zotero/storage/F3KHZ852/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf:application/pdf;INCISE_Transcriptomics_Review.pdf:/Users/neil.hawkins/Zotero/storage/P9L6LPDV/INCISE_Transcriptomics_Review.pdf:application/pdf;integrating-early-economic-evaluation-into-target-product-profile-development-for-medical-tests-advantages-and-potential-applications.pdf:/Users/neil.hawkins/Zotero/storage/UUBAL7DS/integrating-early-economic-evaluation-into-target-product-profile-development-for-medical-tests-advantages-and-potential-applications.pdf:application/pdf;j.1365-2133.2005.06893.x (1).pdf:/Users/neil.hawkins/Zotero/storage/KPF8G2CQ/j.1365-2133.2005.06893.x (1).pdf:application/pdf;jama_277_1_034.pdf:/Users/neil.hawkins/Zotero/storage/F5VWN4XE/jama_277_1_034.pdf:application/pdf;jamacardiol-2-959-s001.pdf:/Users/neil.hawkins/Zotero/storage/HD73A9YH/jamacardiol-2-959-s001.pdf:application/pdf;jamadermatology_armstrong_2020_oi_190067.pdf:/Users/neil.hawkins/Zotero/storage/QJUMEG3R/jamadermatology_armstrong_2020_oi_190067.pdf:application/pdf;jamapsychiatry_miklowitz_2020_oi_200059_1611765271.566.pdf:/Users/neil.hawkins/Zotero/storage/VBW6APQT/jamapsychiatry_miklowitz_2020_oi_200059_1611765271.566.pdf:application/pdf;jcm-10-01272.pdf:/Users/neil.hawkins/Zotero/storage/9LBXR2JQ/jcm-10-01272.pdf:application/pdf;JDV-35-1797-s001 (1).docx:/Users/neil.hawkins/Zotero/storage/SENLQXFA/JDV-35-1797-s001 (1).docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document;JDV-35-1797-s001.docx:/Users/neil.hawkins/Zotero/storage/UW2BX3TT/JDV-35-1797-s001.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document;journal.pone.0246631.pdf:/Users/neil.hawkins/Zotero/storage/W2XFNQQG/journal.pone.0246631.pdf:application/pdf;jtd-09-04-936.pdf:/Users/neil.hawkins/Zotero/storage/6RVYRCCB/jtd-09-04-936.pdf:application/pdf;keaa859.pdf:/Users/neil.hawkins/Zotero/storage/TVU7VVEF/keaa859.pdf:application/pdf;keab321.pdf:/Users/neil.hawkins/Zotero/storage/2MV7T2LU/keab321.pdf:application/pdf;kwx246.pdf:/Users/neil.hawkins/Zotero/storage/SDGDSF4J/kwx246.pdf:application/pdf;kxi047.pdf:/Users/neil.hawkins/Zotero/storage/KJXYAKEG/kxi047.pdf:application/pdf;Learning_about_economic_evaluation_and_health_inequality.pdf:/Users/neil.hawkins/Zotero/storage/BHDF39KN/Learning_about_economic_evaluation_and_health_inequality.pdf:application/pdf;Livingstone 2021.pdf:/Users/neil.hawkins/Zotero/storage/YDS3C2BR/Livingstone 2021.pdf:application/pdf;longpeace.pdf:/Users/neil.hawkins/Zotero/storage/UVUWCQC7/longpeace.pdf:application/pdf;Mahaffey 2019 - Supplement (Inclusion-exclusion).pdf:/Users/neil.hawkins/Zotero/storage/IJUPQWCU/Mahaffey 2019 - Supplement (Inclusion-exclusion).pdf:application/pdf;Mahaffey 2019 Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease.pdf:/Users/neil.hawkins/Zotero/storage/RH4IACN3/Mahaffey 2019 Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease.pdf:application/pdf;Mateos 2018.pdf:/Users/neil.hawkins/Zotero/storage/U8KKZNT6/Mateos 2018.pdf:application/pdf;Mateos 2019.pdf:/Users/neil.hawkins/Zotero/storage/7RT4WGCN/Mateos 2019.pdf:application/pdf;McMurray et al. 2020.pdf:/Users/neil.hawkins/Zotero/storage/INKCETKQ/McMurray et al. 2020.pdf:application/pdf;Mercer - Advanced Science Paper (002).pdf:/Users/neil.hawkins/Zotero/storage/DZ625S39/Mercer - Advanced Science Paper (002).pdf:application/pdf;Mercer 2020.pdf:/Users/neil.hawkins/Zotero/storage/HUQ4662S/Mercer 2020.pdf:application/pdf;methods-proposal-paper.docx:/Users/neil.hawkins/Zotero/storage/M5RD5DNS/methods-proposal-paper.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document;MicroRNA_Biomarkers_for_Infectious_Diseases_From_B.pdf:/Users/neil.hawkins/Zotero/storage/XFRI4L2J/MicroRNA_Biomarkers_for_Infectious_Diseases_From_B.pdf:application/pdf;mmc1 (5).docx:/Users/neil.hawkins/Zotero/storage/3YH799PD/mmc1 (5).docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document;Munshi 2019 (ASH).pdf:/Users/neil.hawkins/Zotero/storage/7BKEDUQ6/Munshi 2019 (ASH).pdf:application/pdf;Munshi 2020.pdf:/Users/neil.hawkins/Zotero/storage/2WB57U2F/Munshi 2020.pdf:application/pdf;nature21349.pdf:/Users/neil.hawkins/Zotero/storage/H8DND25Q/nature21349.pdf:application/pdf;nejmoa1811744_appendix.pdf:/Users/neil.hawkins/Zotero/storage/7SEWE2CJ/nejmoa1811744_appendix.pdf:application/pdf;nejmoa1811744_protocol.pdf:/Users/neil.hawkins/Zotero/storage/BPF8ECEZ/nejmoa1811744_protocol.pdf:application/pdf;nejmoa1914609.pdf:/Users/neil.hawkins/Zotero/storage/BQ4SFP8S/nejmoa1914609.pdf:application/pdf;nejmoa2105215.pdf:/Users/neil.hawkins/Zotero/storage/NVPQWYJ4/nejmoa2105215.pdf:application/pdf;niceimpact-antimicrobial-resistance.pdf:/Users/neil.hawkins/Zotero/storage/4PME5AIY/niceimpact-antimicrobial-resistance.pdf:application/pdf;nihms35861.pdf:/Users/neil.hawkins/Zotero/storage/M66T8D8B/nihms35861.pdf:application/pdf;nihms255748.pdf:/Users/neil.hawkins/Zotero/storage/IXC7WC67/nihms255748.pdf:application/pdf;nihms352464.pdf:/Users/neil.hawkins/Zotero/storage/Y7ZY6VJF/nihms352464.pdf:application/pdf;nihms500204 (1).pdf:/Users/neil.hawkins/Zotero/storage/BGYSFI6F/nihms500204 (1).pdf:application/pdf;nihms500204.pdf:/Users/neil.hawkins/Zotero/storage/9RRDANVT/nihms500204.pdf:application/pdf;NMAPaper.pdf:/Users/neil.hawkins/Zotero/storage/RJYATGXL/NMAPaper.pdf:application/pdf;Not_CE_at_zero_price_FINAL_14.07.14.pdf:/Users/neil.hawkins/Zotero/storage/TTKRVQUJ/Not_CE_at_zero_price_FINAL_14.07.14.pdf:application/pdf;nrd3923.pdf:/Users/neil.hawkins/Zotero/storage/RGC6837C/nrd3923.pdf:application/pdf;PEER_stage2_10.1016_j.spl.2011.02.021.pdf:/Users/neil.hawkins/Zotero/storage/N8P7UH5U/PEER_stage2_10.1016_j.spl.2011.02.021.pdf:application/pdf;Perkovic 2019 Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.pdf:/Users/neil.hawkins/Zotero/storage/N6AEYVUM/Perkovic 2019 Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.pdf:application/pdf;PG_Case_Studies.pdf:/Users/neil.hawkins/Zotero/storage/7WDEBWR6/PG_Case_Studies.pdf:application/pdf;pharmaceutics-12-01240-v2.pdf:/Users/neil.hawkins/Zotero/storage/W93ISVQK/pharmaceutics-12-01240-v2.pdf:application/pdf;PIIS0002914921002071.pdf:/Users/neil.hawkins/Zotero/storage/V48BSTZX/PIIS0002914921002071.pdf:application/pdf;PIIS0025619619310080.pdf:/Users/neil.hawkins/Zotero/storage/E42MTDJQ/PIIS0025619619310080.pdf:application/pdf;PIIS109830151935140X.pdf:/Users/neil.hawkins/Zotero/storage/M977NAES/PIIS109830151935140X.pdf:application/pdf;PIIS0167527321008287.pdf:/Users/neil.hawkins/Zotero/storage/K22V9HFG/PIIS0167527321008287.pdf:application/pdf;PIIS0741521415022168.pdf:/Users/neil.hawkins/Zotero/storage/UEV5UTF4/PIIS0741521415022168.pdf:application/pdf;PIIS0895435618310047.pdf:/Users/neil.hawkins/Zotero/storage/2PF8PNSV/PIIS0895435618310047.pdf:application/pdf;PIIS0923753419349865.pdf:/Users/neil.hawkins/Zotero/storage/MKH945JF/PIIS0923753419349865.pdf:application/pdf;PIIS0959804921003348.pdf:/Users/neil.hawkins/Zotero/storage/J43NGVCE/PIIS0959804921003348.pdf:application/pdf;PIIS1078588412006831.pdf:/Users/neil.hawkins/Zotero/storage/K53NNB5B/PIIS1078588412006831.pdf:application/pdf;PIIS1098301515018471.pdf:/Users/neil.hawkins/Zotero/storage/ZE89JI6Q/PIIS1098301515018471.pdf:application/pdf;PIIS1098301519300518.pdf:/Users/neil.hawkins/Zotero/storage/TULHFIYN/PIIS1098301519300518.pdf:application/pdf;pone.0048877.pdf:/Users/neil.hawkins/Zotero/storage/HY26W9KR/pone.0048877.pdf:application/pdf;pone.0215279 (1).pdf:/Users/neil.hawkins/Zotero/storage/QEQEV5AR/pone.0215279 (1).pdf:application/pdf;pone.0215279 (2).pdf:/Users/neil.hawkins/Zotero/storage/DYHSJ3DB/pone.0215279 (2).pdf:application/pdf;pone.0215279.pdf:/Users/neil.hawkins/Zotero/storage/TP873SS2/pone.0215279.pdf:application/pdf;Population-adjustment-TSD-FINAL-ref-rerun.pdf:/Users/neil.hawkins/Zotero/storage/3BGBNWMW/Population-adjustment-TSD-FINAL-ref-rerun.pdf:application/pdf;postpn_364_Drug_Pricing.pdf:/Users/neil.hawkins/Zotero/storage/9MI85Q5A/postpn_364_Drug_Pricing.pdf:application/pdf;Probability Elicitation Methods for Avoiding Biases_ An Expositio.pdf:/Users/neil.hawkins/Zotero/storage/V2CXIV5W/Probability Elicitation Methods for Avoiding Biases_ An Expositio.pdf:application/pdf;proportionate-universalism-can-be-our-new-normal-martyn-allison-2020.pdf:/Users/neil.hawkins/Zotero/storage/6KSKL4K5/proportionate-universalism-can-be-our-new-normal-martyn-allison-2020.pdf:application/pdf;radiol.2017171920.pdf:/Users/neil.hawkins/Zotero/storage/8D2RWUUR/radiol.2017171920.pdf:application/pdf;radiol.2018182294.pdf:/Users/neil.hawkins/Zotero/storage/8UQVBZEH/radiol.2018182294.pdf:application/pdf;Rondeau2011SMMR_Curefrailty.pdf:/Users/neil.hawkins/Zotero/storage/XLUDPPFS/Rondeau2011SMMR_Curefrailty.pdf:application/pdf;rs140105.pdf:/Users/neil.hawkins/Zotero/storage/8HL6L8KG/rs140105.pdf:application/pdf;s12874-017-0327-3.pdf:/Users/neil.hawkins/Zotero/storage/2B8KVJI2/s12874-017-0327-3.pdf:application/pdf;s12874-017-0405-6.pdf:/Users/neil.hawkins/Zotero/storage/8A6WSHTY/s12874-017-0405-6.pdf:application/pdf;s12939-015-0207-6.pdf:/Users/neil.hawkins/Zotero/storage/TWB8E3PY/s12939-015-0207-6.pdf:application/pdf;s13023-018-0914-3.pdf:/Users/neil.hawkins/Zotero/storage/WECXPAIV/s13023-018-0914-3.pdf:application/pdf;s13023-019-1078-5.pdf:/Users/neil.hawkins/Zotero/storage/FC6IGQ6J/s13023-019-1078-5.pdf:application/pdf;s13643-017-0511-x.pdf:/Users/neil.hawkins/Zotero/storage/5DPEFLG2/s13643-017-0511-x.pdf:application/pdf;s13643-020-01395-6.pdf:/Users/neil.hawkins/Zotero/storage/D9FHGKTF/s13643-020-01395-6.pdf:application/pdf;s40621-018-0174-7.pdf:/Users/neil.hawkins/Zotero/storage/SL2EWIQV/s40621-018-0174-7.pdf:application/pdf;s41429-020-0300-y (1).pdf:/Users/neil.hawkins/Zotero/storage/TUMFCBQN/s41429-020-0300-y (1).pdf:application/pdf;s41429-020-0300-y (2).pdf:/Users/neil.hawkins/Zotero/storage/BNGN2R6K/s41429-020-0300-y (2).pdf:application/pdf;s41429-020-0300-y (3).pdf:/Users/neil.hawkins/Zotero/storage/TSTVCSXL/s41429-020-0300-y (3).pdf:application/pdf;s41429-020-0300-y.pdf:/Users/neil.hawkins/Zotero/storage/HWDWLRM5/s41429-020-0300-y.pdf:application/pdf;s41512-019-0057-6 (1).pdf:/Users/neil.hawkins/Zotero/storage/B8J674XW/s41512-019-0057-6 (1).pdf:application/pdf;s41598-018-37092-7.pdf:/Users/neil.hawkins/Zotero/storage/PK2UX46J/s41598-018-37092-7.pdf:application/pdf;s41598-019-47712-5.pdf:/Users/neil.hawkins/Zotero/storage/J72HUFC7/s41598-019-47712-5.pdf:application/pdf;s42003-021-01832-9.pdf:/Users/neil.hawkins/Zotero/storage/JBG4DVGX/s42003-021-01832-9.pdf:application/pdf;Schnell-Inderst_2017_HE_BiasAdjustedEvidenceSynthesis.pdf:/Users/neil.hawkins/Zotero/storage/JJ9HNL5I/Schnell-Inderst_2017_HE_BiasAdjustedEvidenceSynthesis.pdf:application/pdf;Seeing_the_NICE_side_of_cost-effectiveness_analysi.pdf:/Users/neil.hawkins/Zotero/storage/4NKS7VL7/Seeing_the_NICE_side_of_cost-effectiveness_analysi.pdf:application/pdf;Sheiner-Beal1981_Article_SomeSuggestionsForMeasuringPre.pdf:/Users/neil.hawkins/Zotero/storage/FR4FTSFT/Sheiner-Beal1981_Article_SomeSuggestionsForMeasuringPre.pdf:application/pdf;suppl_material (2).docx:/Users/neil.hawkins/Zotero/storage/PR33TIVM/suppl_material (2).docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document;SupplementaryItems (1).pdf:/Users/neil.hawkins/Zotero/storage/TL4LN86Y/SupplementaryItems (1).pdf:application/pdf;t1189-nationwide-btl-product-guide (9).pdf:/Users/neil.hawkins/Zotero/storage/2L5GVGGB/t1189-nationwide-btl-product-guide (9).pdf:application/pdf;timeROC.pdf:/Users/neil.hawkins/Zotero/storage/886S6IPU/timeROC.pdf:application/pdf;TSD1-Introduction.final_.08.05.12.pdf:/Users/neil.hawkins/Zotero/storage/YFML8RP6/TSD1-Introduction.final_.08.05.12.pdf:application/pdf;TSD3_Heterogeneity.final_report.08.05.12.pdf:/Users/neil.hawkins/Zotero/storage/NUR6R247/TSD3_Heterogeneity.final_report.08.05.12.pdf:application/pdf;Tucker et al. preprint.pdf:/Users/neil.hawkins/Zotero/storage/88HPIMGL/Tucker et al. preprint.pdf:application/pdf;Tumor-Associated_Autoantibodies_Re-Optimization_of.pdf:/Users/neil.hawkins/Zotero/storage/IK73HJ5G/Tumor-Associated_Autoantibodies_Re-Optimization_of.pdf:application/pdf;Unit_Costs_of_Health_and_Social_Care_2020 (1).pdf:/Users/neil.hawkins/Zotero/storage/J7S5RQZF/Unit_Costs_of_Health_and_Social_Care_2020 (1).pdf:application/pdf;UQ269043_OA.pdf:/Users/neil.hawkins/Zotero/storage/IG3XVEZG/UQ269043_OA.pdf:application/pdf;US Valuation of the EQ-5D Health States_Development and Testing of the D1 Valuation Model.pdf:/Users/neil.hawkins/Zotero/storage/UQQM9EYK/US Valuation of the EQ-5D Health States_Development and Testing of the D1 Valuation Model.pdf:application/pdf;Value based decision making for orphan drugs with multiple criteria decision analysis burosumab for the treatment of X linked hypophosphatemia.pdf:/Users/neil.hawkins/Zotero/storage/WX8IFWEM/Value based decision making for orphan drugs with multiple criteria decision analysis burosumab for the treatment of X linked hypophosphatemia.pdf:application/pdf;Visible Analytics Limited - Profit and Loss.pdf:/Users/neil.hawkins/Zotero/storage/PDCFLPWW/Visible Analytics Limited - Profit and Loss.pdf:application/pdf;voluntary-scheme-for-branded-medicines-pricing-and-access-chapters-and-glossary.pdf:/Users/neil.hawkins/Zotero/storage/8EHVZGXZ/voluntary-scheme-for-branded-medicines-pricing-and-access-chapters-and-glossary.pdf:application/pdf;voluntaryarbitrationframeworkforcombinationtherapies_takedawhitepaper_september2021 (1).pdf:/Users/neil.hawkins/Zotero/storage/MUMKWZB5/voluntaryarbitrationframeworkforcombinationtherapies_takedawhitepaper_september2021 (1).pdf:application/pdf;Wheeler et al. 2020.pdf:/Users/neil.hawkins/Zotero/storage/2N98ZIWU/Wheeler et al. 2020.pdf:application/pdf;When-HTA-is-confidential.pdf:/Users/neil.hawkins/Zotero/storage/L7TEUNHB/When-HTA-is-confidential.pdf:application/pdf;Wright2021_Article_AssessingTheQualityAndCoherenc.pdf:/Users/neil.hawkins/Zotero/storage/IMZRAW2R/Wright2021_Article_AssessingTheQualityAndCoherenc.pdf:application/pdf},
}
Downloads: 0
About
Documentation
Keywords
Search
Users
Terms and Conditions of Use
Privacy Policy
Sitemap
© BibBase.org 2021